Investor Event

Turner Pope webinar with Avacta Group plc

This is a third-party event

Avacta’s CEO Dr. Alastair Smith will cover the Company’s updated clinical data from the first-in-human Phase 1 trial of AVA6000, the first of the Company’s pre|CISION™ peptide drug conjugates that targets chemotherapy to the tumor, which are to be presented at the 2024 American Association for Cancer Research Annual Meeting, taking place in San Diego, California from 5-10 April 2024. There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process.

Click here to register